Every payer’s checklist is different.

MARA Rating Insight 

Since 2020, assets with an average Clinical Effectiveness score of 3.1 sailed through HTA evaluations, while those averaging just 2.7 were more often rejected. That 0.4-point gap can mean the difference between green lights and “more data needed.”

Did you know? 

At MARA Rating, we translate the rigorous frameworks of NICE (UK), G-BA/IQWiG (Germany) and ICER (US) into a clear A++ to C score—now covering 350+ assets. Clinical Effectiveness is where you prove your drug’s real-world and comparative impact.

What Is Clinical Effectiveness? 

It’s the evidence payers care about most:

• Real-World Effectiveness: Does your benefit hold up when patients deviate from ideal adherence?
• Key Endpoints: Overall survival, progression-free survival, biomarker shifts—did you hit the metrics that matter?
• Comparative Efficacy: How do you stack up against the current standard of care, whether head-to-head or via robust indirect comparisons?

Strong vs. Marginal Scores

• A++ / A+ / A (“Strong or above”): These assets averaged ≥3.1 in Clinical Effectiveness since 2020—payers see clear value, fast-tracked reviews and stronger pricing leverage.
• B++ to C (“Marginal or below”): Assets averaging ≤2.7 faced more rejections, deeper data requests and tougher negotiations.

Even a single-grade lift can transform your dossier from “nice-to-have” to “must-have.”

Actionable Tips by Role

• Market Access Professionals: Build real-world evidence into your development plan—launch observational cohorts alongside pivotal trials to shore up adherence and safety claims.
• Venture Investors & Acquirers: Prioritize assets with head-to-head comparator data; proven superiority de-risks your portfolio.
• Drug Developers: Broaden inclusion criteria (when scientifically justifiable) and document how your trial’s population boosts generalizability and minimizes payer uncertainty.

See Your Edge Our anonymized score distributions across 350+ assets spotlight exactly where your Clinical Effectiveness evidence stacks up—and where you may face pushback.

Do you know how your product scores? Visit mararating.com or send us a line.

#MarketAccess #HTA #EvidenceStrategy #ClinicalEffectiveness #MARARating #MarketAccessScore